---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: AMPLIFIED"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: AMPLIFIED. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 44 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence/amplified"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: AMPLIFIED

<a id="heading-3.1.3"></a>

## 3.1.3 AMPLIFIED

<a id="heading-3.1.3.1"></a>

### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

#### Purpose stated in the ClinicalTrials.gov brief summary

> “The purpose of the study is to evaluate the efficacy, safety, and tolerability of Inaxaplin (IXP) in participants with proteinuric APOL1- mediated kidney disease (AMKD).”

Source: [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996)

<a id="topic-3.1.3.1-2"></a>

#### Aim stated in the design abstract

> “Given the potential of IXP to treat AMKD, it is essential to assess its efficacy in a broader population, including many of whom have comorbidities that may independently contribute to chronic kidney disease and accelerate disease progression.”
> “Here we describe the design of the proof-of-concept AMPLIFIED study evaluating IXP in persons with AMKD with mild to moderate proteinuria and no comorbidities and people with AMKD with mild to severe proteinuria and significant comorbidities that may worsen kidney dysfunction.”
> “The AMPLIFIED study will provide safety and efficacy data on the potential for IXP to treat a diverse population of AMKD patients with concurrent significant comorbidities associated with proteinuric kidney disease.”

Source: [Chertow et al. (2025b)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20252q319dky~inaxaplin-for-a-broad-population-with-apol1-mediated-kidney)

<a id="topic-3.1.3.1-3"></a>

#### Populations outside the pivotal trial stated by the company

> “AMPLIFIED is a Phase 2, single-arm, open-label study evaluating the effect of treatment with a 45 mg once-daily dose of inaxaplin for 13 weeks to reduce proteinuria in people with AMKD with modest proteinuria, and people with AMKD and type 2 diabetes — populations not being studied in the AMPLITUDE trial.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-3.1.3.1-4"></a>

#### Indication expansion stated in the annual report

> “Our serial innovation strategy in AMKD focuses on indication expansion: evaluating inaxaplin in new populations of people with AMKD not included in the AMPLITUDE clinical trial.”

Source: [Vertex Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm)

<a id="topic-3.1.3.1-5"></a>

#### Planned study announced by the company

> “Vertex plans to initiate AMPLIFIED, a Phase 2b open-label study of inaxaplin in patients with AMKD and diabetes or other co-morbidities currently not eligible for the AMPLITUDE Phase 2/3 pivotal trial, expanding the estimated potentially eligible population from 150,000 to 250,000 patients.”

Source: [Vertex Pharmaceuticals press release, pipeline and business updates (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-provides-pipeline-and-business-updates-advance-upcoming-0)

<a id="heading-3.1.3.2"></a>

### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

#### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual) 2025-02-04”
> “Primary Completion (Actual) 2026-07-20”
> “Study Completion (Actual) 2026-07-20”
> “First Posted 2025-01-27”
> “Last Update Posted 2026-08-20”
> “Completed”
> “No Results Posted”

Source: [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996)

<a id="topic-3.1.3.2-2"></a>

#### Number of locations in the ClinicalTrials.gov record

> “This study has 35 locations”

Source: [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996)

<a id="topic-3.1.3.2-3"></a>

#### Study locations by state in the ClinicalTrials.gov record

| State | Locations listed in the record |
| --- | --- |
| Alabama | “Huntsville, Alabama, United States, 35805” |
| Florida | “Hollywood, Florida, United States, 33023”; “Lauderdale Lakes, Florida, United States, 33313”; “Miami, Florida, United States, 33136”; “Orlando, Florida, United States, 32806” |
| Georgia | “Columbus, Georgia, United States, 31904”; “Decatur, Georgia, United States, 30030”; “Fayetteville, Georgia, United States, 30214”; “Lawrenceville, Georgia, United States, 30046”; “Savannah, Georgia, United States, 31406” |
| Louisiana | “Baton Rouge, Louisiana, United States, 70808”; “Metairie, Louisiana, United States, 70006”; “New Orleans, Louisiana, United States, 70121”; “Shreveport, Louisiana, United States, 71101” |
| Maryland | “Silver Spring, Maryland, United States, 20901” |
| Mississippi | “Columbus, Mississippi, United States, 39705”; “Tupelo, Mississippi, United States, 38801” |
| Nevada | “Las Vegas, Nevada, United States, 89107” |
| New Jersey | “Newark, New Jersey, United States, 07102”; “Newark, New Jersey, United States, 07103” |
| New York | “Laurelton, New York, United States, 11413”; “New York, New York, United States, 10037” |
| North Carolina | “Cary, North Carolina, United States, 27511”; “Chapel Hill, North Carolina, United States, 27599-7155”; “Durham, North Carolina, United States, 27710”; “New Bern, North Carolina, United States, 28562” |
| Pennsylvania | “Philadelphia, Pennsylvania, United States, 19140” |
| South Carolina | “Columbia, South Carolina, United States, 29203”; “Spartanburg, South Carolina, United States, 29306” |
| Texas | “Dallas, Texas, United States, 75230”; “Dallas, Texas, United States, 75237”; “Dallas, Texas, United States, 75246”; “Dallas, Texas, United States, 75390”; “Houston, Texas, United States, 77054” |
| Virginia | “Norfolk, Virginia, United States, 23504” |

Source: [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996)

<a id="topic-3.1.3.2-4"></a>

#### Completion of enrollment reported in the first quarter 2026 results

> “Vertex has completed enrollment in the AMPLIFIED Phase 2 study of inaxaplin.”

Source: [Vertex Pharmaceuticals first quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000171/ex-991_q12026.htm)

<a id="topic-3.1.3.2-5"></a>

#### Completion of enrollment and dosing reported in the second quarter 2026 results

> “Vertex has completed enrollment and dosing in the AMPLIFIED Phase 2 study of inaxaplin and is on track to share data this fall.”

Source: [Vertex Pharmaceuticals second quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000256/ex-991_q22026.htm)

<a id="topic-3.1.3.2-6"></a>

#### Date of the results announcement

> “BOSTON--(BUSINESS WIRE)--Sep. 22, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD) and modest proteinuria and in people with AMKD and type 2 diabetes.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="heading-3.1.3.3"></a>

### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

#### Official title in the ClinicalTrials.gov record

> “A Phase 2b, Open-label Study to Evaluate the Efficacy and Safety of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease With or Without Comorbidities That May Independently Contribute to Chronic Kidney Disease”

Source: [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996)

<a id="topic-3.1.3.3-2"></a>

#### Design details in the ClinicalTrials.gov record

| Field | Registry value |
| --- | --- |
| Study type | “Interventional” |
| Phase | “Phase 2” |
| Primary purpose | “Treatment” |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996)

<a id="topic-3.1.3.3-3"></a>

#### Planned cohorts in the design abstract

> “AMPLIFIED is a phase 2, open-label study evaluating the efficacy of IXP to reduce proteinuria in 45 participants (ages 18-67yrs) with proteinuric AMKD who have none (Cohort 1,n=15) or one of the following significant comorbidities: type 2 diabetes mellitus (Cohort 2,n=15), sickle-cell disease (Cohort 3,n=5), human immunodeficiency virus (Cohort 3,n=5), or lupus nephritis (Cohort 3,n=5).”

Source: [Chertow et al. (2025b)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20252q319dky~inaxaplin-for-a-broad-population-with-apol1-mediated-kidney)

<a id="topic-3.1.3.3-4"></a>

#### Single-arm, open-label design with two reported cohorts

> “AMPLIFIED is a Phase 2, single-arm, open-label study evaluating the effect of treatment with a 45 mg once-daily dose of inaxaplin for 13 weeks to reduce proteinuria in people with AMKD with modest proteinuria, and people with AMKD and type 2 diabetes”
> “Forty-one people were enrolled and dosed in two cohorts”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="heading-3.1.3.4"></a>

### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

#### Key inclusion and exclusion criteria in the ClinicalTrials.gov record

> “Participant has an APOL1 genotype of G1/G1, G2/G2, or G1/G2 obtained with a Vertex designated investigational clinical study assay”
> “Estimated Glomerular Filtration Rate (eGFR) of greater than or equal to (≥) 25 milliliter per minute (mL/min)/1.73m^2 at screening”
> “Evidence of Focal Segmental Glomerulosclerosis (FSGS) with a known cause other than due to APOL1 risk variants”
> “Uncontrolled hypertension”
> “Other protocol defined Inclusion/Exclusion criteria may apply.”

Source: [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996)

<a id="topic-3.1.3.4-2"></a>

#### Age, sex, and healthy volunteers in the ClinicalTrials.gov record

| Field | Registry value |
| --- | --- |
| Ages eligible for study | “18 Years to 67 Years” |
| Sexes eligible for study | “All” |
| Accepts healthy volunteers | “No” |

Source: [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996)

<a id="topic-3.1.3.4-3"></a>

#### Proteinuria thresholds by cohort in the design abstract

> “Participants in Cohort 1 have mild to moderate proteinuria defined as urine albumin-creatinine ratio (UACR) ≥100mg/g to <420mg/g and participants in Cohorts 2 and 3 have mild to severe proteinuria defined as UACR ≥100mg/g to <6000mg/g.”

Source: [Chertow et al. (2025b)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20252q319dky~inaxaplin-for-a-broad-population-with-apol1-mediated-kidney)

<a id="topic-3.1.3.4-4"></a>

#### Proteinuria thresholds by cohort stated with the results

> “1) people with AMKD with modest proteinuria (UACR ≥0.1 g/g to <0.42 g/g) were eligible for cohort 1 (N=23), and 2) people with AMKD, type 2 diabetes and proteinuria (UACR ≥0.1 g/g to <6 g/g) were eligible for cohort 2 (N=18).”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-3.1.3.4-5"></a>

#### Pivotal trial population that AMPLIFIED excludes

> “Vertex has completed full enrollment in the Phase 2/3 AMPLITUDE study of inaxaplin in people with severe proteinuria and no other kidney disease-causing comorbidities.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="heading-3.1.3.5"></a>

### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

#### Arm and intervention in the ClinicalTrials.gov record

> “Experimental: IXP (Inaxaplin)”
> “Participants with proteinuric APOL1-mediated kidney disease (AMKD) with or without the comorbidity of Type 2 diabetes mellitus (T2DM) will receive a single dose of IXP once daily, for 13 weeks.”
> “Tablets for Oral Administration.”

Source: [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996)

<a id="topic-3.1.3.5-2"></a>

#### Dose and background therapy stated with the results

> “In this study, inaxaplin was evaluated as a 45 mg once-daily dose on top of optimized standard of care.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="heading-3.1.3.6"></a>

### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

#### 3.1.3.6.1 Rationale for Using Percent Change in UACR as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

##### Registered primary and secondary outcome measures in the ClinicalTrials.gov record

| Role | Outcome measure | Time frame |
| --- | --- | --- |
| Primary | “Percent Change in Urine Albumin-Creatinine Ratio (UACR)” | “Baseline and At Week 13” |
| Secondary | “Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)” | “From Baseline Up To Week 17” |

Source: [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996)

<a id="topic-3.1.3.6.1-2"></a>

##### Primary and other endpoints stated with the results

> “The primary endpoint in the study was mean percent change in UACR at Week 13 compared to baseline, evaluated separately for each cohort. The other endpoints included mean percent change in urine protein to creatinine ratio (UPCR) at Week 13 compared to baseline and safety.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-3.1.3.6.1-3"></a>

##### Planned endpoints in the design abstract

> “The primary efficacy endpoint will be the percent change from baseline in proteinuria at week 13. Safety will be evaluated.”

Source: [Chertow et al. (2025b)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20252q319dky~inaxaplin-for-a-broad-population-with-apol1-mediated-kidney)

<a id="topic-3.1.3.6.1-4"></a>

##### Albuminuria change as a surrogate endpoint across 48 randomized trials

> “Here, in an individual participant data analysis of 48 randomized controlled trials (studies) involving 85,681 participants, we assessed the association between treatment effects on 6-month urinary albumin:creatinine ratio (UACR) change and the established clinical endpoint of kidney failure or doubling of serum creatinine concentrations.”
> “Across all trials, each 30% reduction in the geometric mean of the UACR in the treatment group relative to the control group was associated with an average of 19% lower hazard for the clinical endpoint (95% Bayesian credible interval (BCI): 5-30%); median coefficient of determination (R2) = 0.66 (95% BCI: 0.06-0.98).”
> “There was no clear evidence that this association varied by CKD etiology.”

Source: [Heerspink et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41198855/)

<a id="topic-3.1.3.6.1-5"></a>

##### Albuminuria change and kidney outcomes in APOL1-mediated kidney disease

> “Recently, proteinuria has been accepted as a surrogate end point for clinical trials in focal segmental glomerulosclerosis (FSGS) ang IgA nephropathy. However, proteinuria has not been evaluated in Apolipoprotein L1 (APOL1)-mediated kidney disease (AMKD).”
> “Real world data (RWD) analysis of 128 patients of African ancestry with APOL1 high risk genotypes, without diabetes, enrolled in the Million Veteran Program (MVP; n=109) or the biorepository at Vanderbilt University (BioVU; n=19), who had urine albumin-creatinine ratio (UACR) >= 420 mg/g (PCR~0.9 g/g) with a concurrent GFR value.”
> “It was estimated that a 50% reduction of UACR at 12 months was associated with a 28% reduction in the kidney composite endpoint (adjusted hazard ratio [aHR]=0.72; 95% confidence interval [CI]:0.59−0.88; p=0.002), and a 38% reduction in the risk of ESKD (aHR=0.62; 95% CI:0.49−0.80; p<0.001).”
> “Changes in UACR at 12 months significantly modify the rate of decline of GFR over 24 months and clinically meaningful endpoints, supporting the use of UACR changes as surrogate endpoint in AMKD.”

Source: [Mamak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13278290/)

<a id="topic-3.1.3.6.1-6"></a>

##### Conditions under which albuminuria reduction is considered a reasonably likely surrogate

> “It was considered that changes in albuminuria may be informative when baseline albuminuria is large and has a dominant role in disease progression and the therapeutic under investigation has a mechanistic relationship to reduce albuminuria.”

Source: [Mamak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13278290/)

<a id="topic-3.1.3.6.1-7"></a>

##### Comparison with the phase 2a result stated by the company

> “These results are in line with the treatment effect previously reported in the Phase 2a study of inaxaplin in AMKD with focal segmental glomerulosclerosis (FSGS), which demonstrated a reduction in UACR of -43.4% and a reduction in UPCR of -47.6% at Week 13 compared to baseline.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="heading-3.1.3.7"></a>

### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

#### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

##### Planned enrollment in the design abstract

> “AMPLIFIED is a phase 2, open-label study evaluating the efficacy of IXP to reduce proteinuria in 45 participants (ages 18-67yrs)”

Source: [Chertow et al. (2025b)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20252q319dky~inaxaplin-for-a-broad-population-with-apol1-mediated-kidney)

<a id="topic-3.1.3.7.1-2"></a>

##### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 42”

Source: [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996)

<a id="topic-3.1.3.7.1-3"></a>

##### Participants dosed and analyzed by cohort stated with the results

| Cohort | Enrolled and dosed | Efficacy analysis | On treatment with a week 13 assessment |
| --- | --- | --- | --- |
| Cohort 1: AMKD with modest proteinuria | “N=23” | “N=22” | “18 and 14 people in cohort 1 and 2, respectively” |
| Cohort 2: AMKD with type 2 diabetes | “N=18” | “N=17” | “18 and 14 people in cohort 1 and 2, respectively” |

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="heading-3.1.3.7.2"></a>

#### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

##### Efficacy analysis set and week 13 analysis population

> “According to the pre-specified statistical analysis plan, two people, one in each cohort, who were noncompliant with treatment, were not included in the efficacy analyses.”
> “Analyses include those on treatment who had an assessment at Week 13: 18 and 14 people in cohort 1 and 2, respectively.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-3.1.3.7.2-2"></a>

##### Geometric mean percent change by cohort and post hoc confidence intervals

> “The primary endpoint in the study was mean percent change in UACR at Week 13 compared to baseline, evaluated separately for each cohort.”
> “Mean % change (geometric) of UACR at Week 13 compared to baseline”
> “95% CI were generated post-hoc”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="heading-3.1.3.8"></a>

### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

#### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

##### Participants enrolled, dosed, and excluded from the efficacy analyses

> “Forty-one people were enrolled and dosed in two cohorts”
> “According to the pre-specified statistical analysis plan, two people, one in each cohort, who were noncompliant with treatment, were not included in the efficacy analyses.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="heading-3.1.3.8.2"></a>

#### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

##### Baseline UACR and UPCR by cohort

| Measure | Cohort 1: AMKD with modest proteinuria | Cohort 2: AMKD with type 2 diabetes |
| --- | --- | --- |
| Mean baseline UACR g/g (standard deviation) | “0.28 (0.09)” | “0.67 (0.87)” |
| Mean baseline UPCR g/g (standard deviation) | “0.46 (0.20)” | “1.12 (1.51)” |

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-3.1.3.8.2-2"></a>

##### FSGS diagnosis and background kidney therapy

> “In this modest proteinuria cohort, most people were not diagnosed with FSGS.”
> “These patients were already well treated with foundational chronic kidney disease therapies and treatment with inaxaplin led to additional reductions in proteinuria.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-3.1.3.8.2-3"></a>

##### FSGS diagnosis in both cohorts stated on the earnings call

> “Of note, the majority of patients in both cohorts did not have a diagnosis of FSGS.”
> “The majority of patients did not have FSGS. So they did not have a biopsy, and they did not have FSGS, which you would expect because their proteinuria is modest and you are correct.”

Source: [Vertex Pharmaceuticals earnings call transcript (2026)](https://www.webull.com/news/15858478693325824)

<a id="heading-3.1.3.8.3"></a>

#### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

##### Percent change in UACR and UPCR at week 13 by cohort

| Endpoint | Cohort 1: AMKD with modest proteinuria | Cohort 2: AMKD with type 2 diabetes |
| --- | --- | --- |
| Primary: geometric mean percent change in UACR at week 13 (95% confidence interval) | “-42.7%”; “(-58.3%, -21.1%)” | “-17.3%”; “(-36.3%, 7.2%)” |
| Other: geometric mean percent change in UPCR at week 13 (95% confidence interval) | “-44.7%”; “(-60.9%, -21.9%)” | “-25.4%”; “(-45.1%, 1.4%)” |

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-3.1.3.8.3-2"></a>

##### Cohort 1: AMKD with modest proteinuria

> “In cohort 1, treatment with inaxaplin administered on top of optimized standard of care led to a reduction of -42.7% (95% CI -58.3%, -21.1%) in UACR at Week 13 compared to baseline. UPCR decreased by -44.7% from baseline at Week 13.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-3.1.3.8.3-3"></a>

##### Cohort 2: AMKD with type 2 diabetes

> “In cohort 2, treatment with inaxaplin administered on top of optimized standard of care led to a reduction in UACR at Week 13 of -17.3% (95% CI -36.3%, 7.2%) compared to baseline. UPCR decreased by -25.4% from baseline at Week 13.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-3.1.3.8.3-4"></a>

##### Results restated in the third quarter 2026 results

> “Vertex announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with AMKD with modest proteinuria (improvement in urine albumin to creatinine ratio [UACR] of -42.7%, and urine protein to creatinine ratio [UPCR] of -44.7%) and people with AMKD and Type 2 diabetes (improvement in UACR of -17.3%, UPCR of -25.4%)”

Source: [Vertex Pharmaceuticals third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm)

<a id="heading-3.1.3.8.4"></a>

#### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

#### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

##### Serious adverse events, severity, headache, and transaminase elevations

> “Inaxaplin was generally safe and well tolerated across both cohorts. There were no serious adverse events (SAEs) related to inaxaplin. All adverse events (AEs) were mild or moderate in severity. The most common AE (occurring in >5% of subjects) was headache (7.3%). Five people had isolated, asymptomatic transaminase elevations, which resolved.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="heading-3.1.3.9"></a>

### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

#### Summary: study limitations

AMPLIFIED was a single-arm, open-label study without a placebo or active comparator, so each cohort's result is a change from baseline over 13 weeks of inaxaplin 45 mg once daily added to “optimized standard of care”. Of 41 participants enrolled and dosed (23 in cohort 1 and 18 in cohort 2), 39 were in the efficacy analyses, and the week 13 analyses included 18 and 14 participants; the registry lists an actual enrollment of 42. The 95% confidence intervals “were generated post-hoc”, and in cohort 2 they include no change for both UACR (-36.3% to 7.2%) and UPCR (-45.1% to 1.4%). The design abstract planned 45 participants, including a third cohort of 15 participants with sickle cell disease, HIV, or lupus nephritis, which the results announcement does not report. The registry lists UACR as the only efficacy outcome measure, and UPCR is reported as an “other” endpoint. All 35 registered sites are in the United States, eligibility was limited to ages 18 to 67 years with eGFR of at least 25 mL/min/1.73 m2, and the only baseline characteristics reported are mean UACR and UPCR by cohort. The study measured no kidney function outcome. The AMKD-specific analysis supporting UACR change as a surrogate endpoint used 12-month changes in 128 participants without diabetes and with UACR of at least 420 mg/g, a range that excludes the cohort 1 eligibility range (UACR at least 100 to below 420 mg/g) and the cohort 2 population. As of 2026-11-15 the results are available only from company communications: the registry shows “No Results Posted”, and no peer-reviewed publication or congress presentation of the results was identified.

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study); [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996); [Chertow et al. (2025b)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20252q319dky~inaxaplin-for-a-broad-population-with-apol1-mediated-kidney); [Mamak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13278290/)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
